Sage Therapeutics’ SAGE-217 Receives FDA’s Breakthrough Designation for CNS Disorders

 Sage Therapeutics’ SAGE-217 Receives FDA’s Breakthrough Designation for CNS Disorders

Sage Therapeutics’ Zulresso (brexanolone) Receives FDA’s Approval for Postpartum Depression (PPD)

Shots:

  • The FDA’s BT Designation is based on P-II study assessing SAGE-217 vs PBO in 89 patients with moderate to severe major depressive disorder (MDD)
  • The P-II study results: met 1EPs; reduction in the Hamilton Rating Scale for Depression (HAM-D); safe, effective & well tolerated data
  • SAGE-217 (qd, PO) is an allosteric modulator targeting synaptic & extrasynaptic GABA receptors used for regulating CNS function and is currently developed for MDD, Parkinson’s disease and sleep disorders

Click here to read full press release/ article | Ref: Sage Therapeutics | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post